NCT02004028 2024-02-20Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma ParticipantsVerastem, Inc.Phase 2 Terminated35 enrolled 15 charts
NCT02372227 2017-01-30A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant MesotheliomaVerastem, Inc.Phase 1 Terminated21 enrolled